Clinical Trials Logo

Clinical Trial Summary

This is a pilot, randomized, single-center, parallel group, open-label controlled study to evaluate the feasibility, safety, efficacy, and pharmacokinetics of nebulized HCQ01 plus Standard of Care (SOC) versus SOC alone in hospitalized COVID-19 patients. The Jordanian Ministry of Health (MOH) is the study sponsor, and the study will be conducted at MOH COVID-19 hospitals. Approximately 110 patients, ≥18 years of age with a confirmed SARS-CoV-2 infection, will be enrolled and randomized 1:1 to the treatment and control arms where they will receive ten doses of Hydroxychloroquine solution via nebulizer in addition to SOC or the control arm where treatment will follow the MOH SOC.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05113810
Study type Interventional
Source Ministry of Health Jordan
Contact Yasmeen Dodin, MSc
Phone 00962798950958
Email [email protected]
Status Not yet recruiting
Phase Phase 2
Start date December 4, 2021
Completion date May 4, 2022

See also
  Status Clinical Trial Phase
Suspended NCT04334967 - Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care Phase 4
Not yet recruiting NCT04731051 - The Potential Use of Inhaled Hydroxychloroquine for the Treatment of COVID-19 in Cancer Patients Phase 1/Phase 2
Not yet recruiting NCT04246242 - A Randomized Multicenter Controlled Clinical Trial of Arbidol in Patients With 2019 Novel Coronavirus (2019-nCoV) Phase 4